Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Vycor Medical (VYCO) Other financing activities (2015 - 2021)

Vycor Medical (VYCO) reported Other financing activities of $20839.0 for Q3 2021, up 48.85% year-over-year from $14000.0 in Q3 2020, and up 18379.82% on a QoQ basis from -$114.0 in Q2 2021.

Vycor Medical (VYCO) has 6 years of Other financing activities data on file, last reported at $20839.0 in Q3 2021.

  • Quarterly Other financing activities rose 48.85% year-over-year to $20839.0 in Q3 2021, while the trailing twelve-month figure through Mar 2022 was $20725.0 (down 70.39% YoY) and the FY2021 annual result came in at $21000.0, down 70.0% from the prior year.
  • Other financing activities improved to $20839.0 in Q3 2021 per VYCO's latest filing, from -$114.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $88456.0 in Q4 2018 and bottomed at -$88456.0 in Q3 2018.
  • The 4-year median for Other financing activities is $20839.0 (2021), against an average of $16092.6.
  • Peak annual rise in Other financing activities reached 10404.2% in 2017, while the deepest fall reached 53737.29% in 2017.
  • Tracing VYCO's Other financing activities over 4 years: stood at -$31646.0 in 2017, then jumped by 379.52% to $88456.0 in 2018, then slumped by 84.17% to $14000.0 in 2020, then jumped by 48.85% to $20839.0 in 2021.
  • Per Business Quant, the three latest VYCO Other financing activities figures stand at $20839.0 (Q3 2021), -$114.0 (Q2 2021), and $21000.0 (Q1 2021).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Vycor Medical - - 375,153.00

Historic Data

Download Data 🔒
DateValue
Sep 30, 2021 20,839.00
Sep 30, 2021 20,839.00
Jun 30, 2021 -114.00
Jun 30, 2021 -114.00
Mar 31, 2021 21,000.00
Mar 31, 2021 21,000.00
Dec 31, 2020 14,000.00
Dec 31, 2020 14,000.00
Sep 30, 2020 14,000.00
Sep 30, 2020 14,000.00
Jun 30, 2020 21,000.00
Jun 30, 2020 21,000.00
Mar 31, 2020 21,000.00
Mar 31, 2020 21,000.00
Sep 30, 2018 528.00
Sep 30, 2018 528.00
Jun 30, 2018 86,754.00
Jun 30, 2018 86,754.00
Mar 31, 2018 4,871.00
Mar 31, 2018 4,871.00
Dec 31, 2017 -1.00
Dec 31, 2017 -1.00
Sep 30, 2017 37,500.00
Sep 30, 2017 37,500.00
Dec 31, 2016 59.00
Dec 31, 2016 59.00
Sep 30, 2016 357.00
Sep 30, 2016 357.00
Mar 31, 2016 6,250.00
Mar 31, 2016 6,250.00
Dec 31, 2015 1.00
Dec 31, 2015 1.00
Sep 30, 2015 -2,172.00
Sep 30, 2015 -2,172.00
Mar 31, 2015 6,250.00
Mar 31, 2015 6,250.00